Cargando…

Aiding the discovery of new treatments for dementia by uncovering unknown benefits of existing medications

INTRODUCTION: There is a significant need for disease-modifying therapies to treat and prevent dementia, including Alzheimer's disease. Availability of real-world observational information and new analytic techniques to analyze large volumes of data can provide a path to aid drug discovery. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Kern, David M., Cepeda, M. Soledad, Lovestone, Simon, Seabrook, Guy R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909196/
https://www.ncbi.nlm.nih.gov/pubmed/31872043
http://dx.doi.org/10.1016/j.trci.2019.07.012
Descripción
Sumario:INTRODUCTION: There is a significant need for disease-modifying therapies to treat and prevent dementia, including Alzheimer's disease. Availability of real-world observational information and new analytic techniques to analyze large volumes of data can provide a path to aid drug discovery. METHODS: Using a self-controlled study design, we examined the association between 2181 medications and incidence of dementia across four US insurance claims databases. Medications associated with ≥50% reduction in risk of dementia in ≥2 databases were examined. RESULTS: A total of 117,015,066 individuals were included in the analysis. Seventeen medications met our threshold criteria for a potential protective effect on dementia and fell into five classes: catecholamine modulators, anticonvulsants, antibiotics/antivirals, anticoagulants, and a miscellaneous group. DISCUSSION: The biological pathways of the medications identified in this analysis may be targets for further research and may aid in discovering novel therapeutic approaches to treat dementia. These data show association not causality.